Institutional accumulation regime. Strong business quality combined with supportive market trend. Valuations remain demanding and supported by current metrics.
SENTINEL REVIEW
Bafna Pharmaceuticals Limited (BAFNAPH)•Updated yesterday
🚨 Structural Deterioration Signature: In FY2026, Bafna Pharmaceuticals Limited is experiencing severe operating deterioration, marked by a 167.3% YoY surge in reported net profit to ₹11.1 Cr, following a prior loss of ₹4.2 Cr. Profitability is being hollowed out by intensifying margin compression: EBIT margins fell to 6.5% from 9.7% YoY, signaling significant internal efficiency stress. This operating deterioration is reflected in a severe inventory-revenue divergence: inventory build-up of 12.8% stands against a 11.4% quarterly revenue contraction, contributing to a 30.6% drop in operating cash flow to ₹15.4 Cr. Against this liquidity strain, total debt expanded 32.7% to ₹37.4 Cr, pushing interest coverage down to 1.08x and entering Flagium's heightened surveillance range.
- ✗Risk score deteriorated (QoQ change: +10 pts)
- ✓Profitability margins pressure eased
- ✗New risk trigger: Low Interest Coverage (+10.6 pts)
- ✗Growth expectations are demanding
- ✓Market structure is strong
- ✗Institutional flow regime is Neutral (-0.28σ)
- ✓Share price is up +21.6% this quarter (from ₹371.35 on 30 Sept to ₹451.6)
- 🟢No severe forensic red flags active for BAFNAPH
- 🟠Track earnings quality and working capital trends in next filing
- 🟢Maintain routine quarterly surveillance; no governance escalation required
- 10.6 ptsBalance Sheet Stress
- 10.0 ptsGrowth Sustainability
- 5.5 ptsEarnings Quality
- 9.0 ptsMacro & Sector Calibration
Divergence Radar
Structural Matrix
Risk vs Price TimelineVisualizing the historical relationship between the structural risk score and stock price movement over time.
| Duration | Perf. | Sector Avg | Divergence |
|---|---|---|---|
| 1 Week | -2.07% | -1.46% | -0.61% |
| 1 Month | +26.48% | -6.69% | +33.17% |
| 6 Months | +237.01% | +6.82% | +230.19% |
| 1 Year | +233.65% | +8.93% | +224.73% |
| 2 Year | +457.53% | +47.64% | +409.89% |
| 3 Year | +443.77% | +125.5% | +318.27% |
Business Analysis Methodology
Business analysis focuses on structural risk inside the company. Flagium monitors earnings quality, balance sheet strength, liquidity, governance, competitive position, and growth sustainability to identify areas where risk may be increasing or decreasing before it becomes obvious in reported results.
Financial profile remains stable for now. Weakness is detected in balance sheet stress. This suggests a building risk profile. Risk is increasing at a faster pace.
Risk Score Composition
Investment Risk Thesis
Current risk score has risen from 6 → 35 over 14 quarters.
- Operating cash flow sustainability
- Working capital discipline
Risk Drivers (Active Warnings)
No active warnings detected.
Primary Driver & Insights
Forensic risk profile is stable. No severe operating or financial anomalies are currently pressure-testing business resilience.
Active Risk Objects (9)Free Preview (2 of 9)
BAFNAPH: EBITDA margin compressed by 3.2 bps YoY.
Operating efficiency is stabilizing. The rate of margin deterioration has slowed.
BAFNAPH: Low Interest Coverage Ratio of 1.08x in FY2027 Q1 (Threshold: 2.5x).
The ability to cover interest is strengthening as earnings improve or debt is retired.
Unlock All 9 Forensic Signals (7 Additional Warnings Gated)
Free accounts preview the top 2 highest-impact warning signals. Upgrade to Flagium Pro to inspect all 9 active forensic detectors, multi-quarter duration streaks, and financial stress metrics for Bafna Pharmaceuticals Limited.
Statutory Note: Forensic signals are algorithmic quantitative observations derived from publicly filed XBRL disclosures and do not constitute allegations of legal misconduct or investment recommendations.
Unlock Interactive Signal Evidence Dossier
Access complete multi-quarter financial evidence, 5-KPI snapshot strips, diagnostic hypotheses, and 1-page forensic PDF dossiers for Bafna Pharmaceuticals Limited.
Structural Risk Attribution
Deterministic quarter-on-quarter causal decomposition grounded in statutory exchange filings.
Structural History · Last 12 QuartersHistorical Trajectory (12Q)
Risk deteriorated notably (+10.0 pts), driven by new Low Interest Coverage (+10.6 pts) and new Profit Collapse (+7.4 pts).
12-Quarter Structural Regimes & Landmark Inflections12Q Structural Regimes & Inflections
Risk deteriorated materially (+25.0 pts), driven by new Inventory Stress (+16.2 pts) and new Relative Growth Weakness (+13.0 pts).
Business Resilience & Benchmark Context
Overall: HEALTHYPEER COMPARISON MATRIX
Ranked surveillance & credit risk comparison against sector peers
Stable
Stable
Stable
Watch
Watch
Watch
* Peer comparison is based on risk signals, not valuation or returns.
Unlock 5-Year Forensic Divergence Cockpit
Access multi-year visual divergence charts (EBITDA vs CFO Cash Gap, Receivables Decoupling Spread, and Debt vs FCF Burn) for Bafna Pharmaceuticals Limited.
FINANCIAL STATEMENTS
Working Capital & Forensic Monitor
Operating Cycle Disclosures·9 Fiscal Years
Working Capital Schedule (INR Cr)
| Metric / Ratio | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|
Trade Receivables(₹ Cr) | — | — | — | — | — | — | — | — | — |
Inventories(₹ Cr) | — | — | — | — | — | — | — | — | — |
Trade Payables(₹ Cr) | — | — | — | — | — | — | — | — | — |
Net Working Capital(₹ Cr) | — | — | — | — | — | — | — | — | — |
Working Capital / Sales(%) | — | — | — | — | — | — | — | — | — |
Cash Conversion & Operating Cycle (Days)
| Metric / Ratio | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|
Cash Conversion Cycle (CCC)(days) | — | — | — | — | — | — | — | — | — |
Debtor Days (DSO)(days) | — | — | — | — | — | — | — | — | — |
Inventory Days (DIO)(days) | — | — | — | — | — | — | — | — | — |
Creditor Days (DPO)(days) | — | — | — | — | — | — | — | — | — |
Forensic Accounting Monitor & Divergences
| Metric / Ratio | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|
Receivable Growth vs Sales (Δ)(%) | — | — | — | — | — | — | — | — | — |
Inventory Growth vs Sales (Δ)(%) | — | — | — | — | — | — | — | — | — |
Asset Growth vs Sales (Δ)(%) | — | -9.4% | +6.8% | +15.8% | +8.9% | +32.3% | -15.3% | -16.5% | — |
Earnings-to-Cash Divergence (PAT - CFO)(₹ Cr) | — | -16 | -10 | -18 | -16 | -5 | -1 | -33 | -27 |
Accrual Ratio (Accruals / Avg Assets)(%) | — | -12.4% | -6.3% | -9.7% | -8.1% | -2.3% | -0.4% | -13.8% | -12.3% |
Operating Cash Realisation (CFO / EBITDA)(%) | — | — | — | — | 100.0% | — | 8.7% | 168.2% | 152.6% |
Capitalisation Intensity (CWIP / Assets)(%) | — | — | — | — | — | — | — | — | — |
Industry Intelligence
Pharmaceutical Sector KPIs| Operating Driver | Quarter | Current Value | Change (QoQ) | Change (YoY) | Industry Median |
|---|---|---|---|---|---|
| Q4 FY2020 | 48.6% | — | — | 64.0% |
Understanding Pharmaceutical KPIs
Concall & Management Takeaways
No investor earnings call transcripts transcribed for this scrip.
Earnings call intelligence is automatically populated when companies conduct quarterly earnings calls with institutional investors and publish transcripts.
Business quality remains stable.
Current forensic pressure is elevated and stable.
Key risks remain concentrated in growth sustainability and operating leverage.
The risk profile is Early Signals and currently deteriorating. Recent structural triggers in balance sheet stress suggest a building pressure on the underlying framework. Material forensic traces are visible in core structural metrics, indicating a progressive erosion of structural stability. Strategic vigilance is advised as structural decay is accelerating.
Market Expectation Engine
Investor Translation • What the market price is expecting
Expectation EngineAt the current price of ₹452, the market expects this company to grow its revenue by 20.5% every year for the next 5 years. If you think the company will grow faster than 20.5%, current market prices reflect a discount relative to that growth assumption.
Sentinel Takeaway:The market expects future growth significantly above the company's historical delivery. Current market expectations appear demanding relative to the business's track record, resulting in higher expectation risk.
Using the Implied Revenue Model, the market is pricing BAFNAPH for 20.5% implied revenue growth versus 9.4% observed 3Y revenue CAGR. Current expectations appear demanding, and trailing fundamentals provide moderate support.
Business Delivery Capacity
Performance quality vs historical benchmarksHistorical business performance currently provides moderate support for the market's implied growth assumptions. Improvement in revenue growth and operating efficiency would strengthen expectation support.
WHY IS EXPECTATION RISK ELEVATED?
Valuation Context
WHAT MUST HAPPEN FOR CURRENT PRICE TO BE CORRECT?
| Assumption Metric | Required (To justify current price) | Historical Delivery (Average) | Fulfillment Assessment |
|---|---|---|---|
| Revenue Growth (CAGR) | 20.5% | 9.4% | Demanding |
| Operating Margin (EBIT) | 5.1% | 5.3% | Achievable |
| Free Cash Flow Conversion | -124.5% | -55.1% | Achievable |
*Required metrics indicate the operating efficiency and revenue expansion parameters that must be sustained long-term to justify the current stock price.
The current valuation assumes business performance well above the company's historical record. Historical operating performance currently provides limited evidence that these expectations are sustainable. Continued stronger profitability and stronger cash generation would be required to justify current pricing.
Market Structure Methodology
Flagium separates Business Risk from Market Structure. Business analysis explains what is happening inside the company. Market Structure measures how investors are behaving through price trends, momentum, participation, and institutional activity. Divergences between the two often reveal important transitions before they become obvious.
The stock remains in a confirmed Stage 2 advancing phase. Institutional participation remains neutral, while trend quality stays constructive and momentum is accelerating. Current price action continues to support the prevailing advance.
What Is Driving Market Structure?
Market behavior shows signs of strength while underlying fundamental risk is elevated.
Market Cycle Stage Analysis
Stan Weinstein 4-Stage CycleMomentum & Institutional Flow
Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics and research platform providing quantitative risk, forensic, and valuation analytics for informational and educational purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. These analytics do not constitute financial planning, investment advice, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.
📬 Flagium Risk Brief — Track forensic risks on BAFNAPH & 3 market anomalies weekly
See a sample issue →